Protagonist Therapeutics
PTGX
81 hedge funds and large institutions have $164M invested in Protagonist Therapeutics in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 13 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
13.19% more ownership
Funds ownership: 72.06% → 85.25% (+13%)
7% more funds holding
Funds holding: 76 → 81 (+5)
28% less capital invested
Capital invested by funds: $228M → $164M (-$64M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$16.9M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$6.26M |
| 3 |
BlackRock
New York
|
+$4.75M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$2.48M |
| 5 |
O
OrbiMed
New York
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management III
New York
|
-$9.85M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.03M |
| 3 |
VMI
VHCP Management II
New York
|
-$3.92M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.95M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.89M |
PTGX Hedge Fund Activity: Q4 2019 in Review
81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2019, worth a combined $164M — down 28% from $228M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PTGX positions and 13 closed out — a net gain of 5 holders — while 34 added to existing stakes and 15 trimmed.
The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was VHCP Management III, cutting an estimated $9.85M.
- 81 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2019, up from 76 in Q3 2019.
- Funds reported $164M of Protagonist Therapeutics stock for Q4 2019, down 28% quarter-over-quarter.
- 18 funds opened new Protagonist Therapeutics positions in Q4 2019 and 13 closed out, a net change of +5 holders.
- The largest Protagonist Therapeutics buyer in Q4 2019 was RTW Investments, an estimated $16.9M added.
- The largest Protagonist Therapeutics seller in Q4 2019 was VHCP Management III, an estimated $9.85M sold.
Based on aggregated 13F filings for Q4 2019.